Nonvoluntary Psychiatric Treatment Is Distinct From Involuntary Psychiatric Treatment

JAMA. 2017; 318(11): 999-1000.
Author: Dominic A. Sisti
“Some of the most ethically challenging cases in mental health care involve providing treatment to individuals who refuse that treatment. Sometimes when persons with mental illness become unsafe to themselves or others, they must be taken, despite their outward and often vigorous refusal, to an emergency department or psychiatric hospital to receive treatment, such as stabilizing psychotropic medication. On occasion, to provide medical care over objection, a patient must be physically restrained.”
Find article here.

‘Shocking’ disregard for safety in U.S. meningitis case -prosecutor

Reuters, 21 September 2017
Author: Nate Raymond
“A federal prosecutor on Tuesday accused a Massachusetts pharmacist charged with murder for his role in a deadly 2012 U.S. meningitis outbreak of showing a “shocking” disregard for patients’ lives, while his lawyer argued the man was no killer.”
Find article here.

France to prosecute its drug regulator and Servier in scandal over diabetes drug

BMJ 2017; 358: j4231
Author: Owen Dyer
“France’s drug regulator and one of its leading drug companies, Servier, will stand trial as legal persons over the marketing of the antidiabetes and weight loss drug benfluorex (marketed in France as Mediator), which is believed to have killed between 500 and 2300 people before being pulled from the market in 2009.”
Find article here.

Seven Network Limited v South Eastern Sydney Local Health District [2017] NSWCATAD 210

Decision date: 27 June 2017
“Government Information (Public Access) – application for disclosure of CCTV footage of assaults on staff at hospitals – whether overriding public interest against disclosure – disclosure of personal information and health information – disclosure prejudicing the effective exercise of the agency’s functions – whether pixelation of faces and identifying marks would avoid concerns – impact on operations of hospitals if footage recording treatment of patients was released.”
Find decision here.

A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia

BMJ Open 2017; 7: e016701.
Authors: Fabbri A, Grundy Q, Mintzes B, et al
“To analyse patterns and characteristics of pharmaceutical industry sponsorship of events for Australian health professionals and to understand the implications of recent changes in transparency provisions that no longer require reporting of payments for food and beverages.”
Find article here.

The case for an Indigenous Bioethics

Global Bioethics Blog, 25 June 2017
Author: Stuart Rennie
“Indigenous communities in the Americas experience a disproportionate incidence of illness and disease compared to the general population. They also possess sophisticated ethical traditions which diverge and not infrequently conflict with Western-oriented bioethics. This culture gap between patient, provider and ethicist is no small public health concern—it can foster feelings of alienation and distrust which compromise the relationship between those in need of care and those able to offer it. Research ethicists have already made considerable efforts to bring sensitivity for aboriginal cultural mores into their discipline, but bioethicists have been slower out of the gate.”
Find article here.